Letters To The Editor Open Access
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Apr 25, 2016; 7(8): 175-176
Published online Apr 25, 2016. doi: 10.4239/wjd.v7.i8.175
Comment on: Statin use and risk of diabetes mellitus
Mehmet Ali Eren, Tevfik Sabuncu, Hüseyin Karaaslan, Department of Endocrinology, Harran University, School of Medicine, 63100 Sanliurfa, Turkey
Author contributions: Eren MA and Karaaslan H wrote this letter; Sabuncu T edited and revised this letter.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Mehmet Ali Eren, MD, Department of Endocrinology, Harran University, School of Medicine, Valikonagi Street, Yenisehir Campus, 63100 Sanliurfa, Turkey. drmalieren@hotmail.com
Telephone: +90-414-3128456
Received: December 11, 2015
Peer-review started: December 14, 2015
First decision: January 4, 2016
Revised: January 22, 2016
Accepted: February 16, 2016
Article in press: February 17, 2016
Published online: April 25, 2016
Processing time: 125 Days and 15.9 Hours

Abstract

In manuscript named “Statin use and risk of diabetes mellitus” by Chogtu et al, authors defined that pravastatin 40 mg/dL reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study. In fact, pravastatin 40 mg/dL reduced coronary heart disease risk approximately 30% in mentioned study.

Key Words: Pravastatin; Statins; Diabetes mellitus; Coronary heart disease; Myocardial Infarction

Core tip: We want to eliminate an important error that lead to confusion about the risk of diabetes due to statins in the well-written manuscript by Chogtu et al.
TO THE EDITOR

We read with great interest the recent review by Chogtu et al[1] ealing with the risk of diabetes mellitus development induced by the use of statins. The authors clearly explained the benefit of statin on cardiovascular prevention as well as the possible mechanism of impaired glucose metabolism related with statin. In our opinion, there was a critical confusing error in “statins in diabetes” section.

In the last sentence of mentioned section, authors defined that pravastatin 40 mg/dL reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study with reference to the Kotseva et al[2]. However, pravastatin 40 mg/dL reduced nonfatal myocardial infarctions risk by 31%, death from coronary heart disease by 28%, death from all cardiovascular causes by 32% but there was no information about diabetes risk in the original study of West of Scotland Coronary Prevention Study Group[3].

We hope that the correction of above-mentioned item would eliminate the confusion and provide better understanding of the well-written manuscript by Chogtu et al[1].

Footnotes

P- Reviewer: Laguna JC, Markopoulos AK, Nagaya M S- Editor: Ji FF L- Editor: A E- Editor: Liu SQ

References
1.  Chogtu B, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. World J Diabetes. 2015;6:352-357.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 41]  [Cited by in F6Publishing: 42]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
2.  Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-940.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 602]  [Cited by in F6Publishing: 618]  [Article Influence: 41.2]  [Reference Citation Analysis (0)]
3.  Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5406]  [Cited by in F6Publishing: 5072]  [Article Influence: 174.9]  [Reference Citation Analysis (0)]